Patents by Inventor Katherine Vousden

Katherine Vousden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL33 ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20240016929
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 18, 2024
    Inventors: Emma S. COHEN, David C. LOWE, Robin BUTLER, Ian C. SCOTT, Katherine A. VOUSDEN, Martin D. STRAIN, Sara CARMEN, Elizabeth H. ENGLAND, Benjamin P. KEMP, David G. REES, Catherine L. OVERED-SAYER, Tomas M. MUSTELIN, Matthew SLEEMAN, Kirsty HOUSLAY
  • Polynucleotides encoding IL33 antibodies and methods of using the same
    Patent number: 11738081
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: August 29, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay
  • NOVEL IL33 FORM, MUTATED FORMS OF IL33, ANTIBODIES, ASSAYS AND METHODS OF USING THE SAME
    Publication number: 20200353078
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Application
    Filed: April 10, 2020
    Publication date: November 12, 2020
    Inventors: Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay
  • IL33 form, mutated forms of IL33, antibodies, assays and methods of using the same
    Patent number: 10668150
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: June 2, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay
  • A NOVEL IL33 FORM, MUTATED FORMS OF IL33, ANTIBODIES, ASSAYS AND METHODS OF USING THE SAME
    Publication number: 20180207265
    Abstract: The present invention provides isolated IL-33 proteins, active fragments thereof and antibodies, antigen binding fragments thereof, against IL-33 proteins. Also provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders.
    Type: Application
    Filed: March 30, 2016
    Publication date: July 26, 2018
    Inventors: Emma S. Cohen, David C. Lowe, Robin Butler, Ian C. Scott, Katherine A. Vousden, Martin D. Strain, Sara Carmen, Elizabeth H. England, Benjamin P. Kemp, David G. Rees, Catherine L. Overed-Sayer, Tomas M. Mustelin, Matthew Sleeman, Kirsty Houslay
  • Cca1 as an antifungal target
    Publication number: 20060240493
    Abstract: The invention provides ATP(CTP): tRNA nucleotidyltransferase (CCA1) as a novel antifungal target, screening methods for CCA1 inhibitors and their use as antifungal compounds, pharmaceutical compositions containing them and their use in medicine. Specifically in the treatment of an individual susceptible to or suffering from an anti-fungal infection. In particular the compounds find use in the treatment of topical or mucosal (e.g. thrush and vaginal candidiasis) fungal infections, e.g. caused by fungus of the Candida species, and for systemic infections, e.g. caused by fungi of Candida and Aspergillus species, such as but not limited to C. Albicans, Aspergillus flavus or Aspergillus fumigatus.
    Type: Application
    Filed: December 9, 2003
    Publication date: October 26, 2006
    Inventor: Katherine Vousden
  • CGT1 as an antifungal target
    Publication number: 20060172368
    Abstract: The invention provides CGT1 guanylyltransferase (CGT1) as a novel antifungal target, screening methods for CGT1 inhibitors and their use as antifungal compounds, pharmaceutical compositions containing them and their use in medicine.
    Type: Application
    Filed: December 9, 2003
    Publication date: August 3, 2006
    Inventor: Katherine Vousden